{"id":"W2159370562","doi":"10.1093/eurheartj/ehr334","title":"RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome","year":2011,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":185,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"Servier; Astellas Pharma","keywords":"Medicine; Tolerability; Placebo; Acute coronary syndrome; Randomized controlled trial; Double blind; Internal medicine; Adverse effect; Myocardial infarction; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001791804,0.002443554,0.004129665,0.0005030771,0.0004385681,0.001293329,0.001234046,0.002418318,0.005536774],"category_scores_gemma":[0.002418116,0.000841099,0.001644797,0.0003624696,0.001709948,0.001342546,0.0006111186,0.003226849,0.001058085],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006647386,"about_ca_system_score_gemma":0.001057251,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007999177,"about_ca_topic_score_gemma":0.001623985,"domain_scores_codex":[0.9991915,0.0004315652,0.00004575381,0.0001474758,0.0000597237,0.0001240735],"domain_scores_gemma":[0.9991847,0.0001868546,0.0002474218,0.00006737668,0.00004018866,0.0002735838],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9874704,0.002751421,0.0002846496,0.0007115816,0.0005597864,0.00003035521,0.00002786356,0.000118612,0.001992135,0.00007039877,0.0003706455,0.005612197],"study_design_scores_gemma":[0.9793509,0.0194155,0.000582042,0.00001643794,0.0001962852,0.00001582713,0.000006612689,0.0001141483,0.00013388,0.00003824032,0.0001244395,0.0000056938],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9836109,0.007952676,0.0007548264,0.0009510548,0.0008609552,0.003318483,0.000878534,0.0002203201,0.001452225],"genre_scores_gemma":[0.9845904,0.004056905,0.001765174,0.001399883,0.0008319512,0.003710205,0.001114664,0.00003321317,0.002497598],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005536774,"threshold_uncertainty_score":0.01852232,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1060709866182456,"score_gpt":0.3253483990563421,"score_spread":0.2192774124380965,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}